Skip to main content

Table 1 Patient characteristics

From: MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

Variable

Total no.

MTDH expression

Pvalue*

High

Low

 
  

No.

%

No.

%

 

Age

      

 <50

40

24

20.3

16

13.6

 

 ≥50

78

50

42.4

28

23.7

0.663

Nodal status

      

 Positive

82

58

49.2

24

20.3

 

 Negative

36

16

13.6

20

16.9

0.007

Stage

      

 I

20

7

5.9

13

11.0

 

 II

27

17

14.4

10

8.5

 

 III

25

18

15.3

7

5.9

 

 IV

46

32

27.1

14

11.9

0.038

Grade

      

 1

28

14

11.9

14

11.9

 

 2

43

31

26.3

12

10.2

 

 3

47

29

24.5

18

15.2

0.167

ER status

      

 Positive

66

40

33.9

26

22.0

 

 Negative

52

34

28.8

18

15.3

0.594

PR status

      

 Positive

60

36

30.5

24

20.3

 

 Negative

58

38

32.2

20

17.0

0.536

Ki67

      

 High index

78

52

44.1

23

19.5

 

 Low index

40

22

18.6

21

17.8

0.015

  1. *Chi square test or Fisher’s exact test.